The data, which was presented at the Society for Pediatric Anesthesia Meeting in Fort Myers, Florida, also showed ALGRX 3268 was well tolerated.
Corgentech plans to file a new drug application (NDA) with the FDA in mid-2006 for the drug, the first of three product candidates the company is developing for pain management.
ALGRX 3268 utilizes a needleless injection system to locally deliver lidocaine into the skin to anesthetize the skin and relieve pain very rapidly. Approximately 18 million venipunctures and intravenous line placements occur each year in the largest children’s hospitals and academic institutions in the US.
“With an onset of action of one to three minutes, ALGRX 3268 provides a unique fast-acting, local anesthetic for reducing pain associated with peripheral venous access and intravenous insertion procedures in children,” said Dr Elliot Krane, principal investigator for the study and the director of pain management at the Lucile Packard Children’s Hospital.